Salud financiera de hoja de balance de Anixa Biosciences
Salud financiera controles de criterios 6/6
Anixa Biosciences tiene un patrimonio de los accionistas total de $20.7M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $22.9M y $2.2M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$20.75m |
| Patrimonio | US$20.69m |
| Total pasivo | US$2.22m |
| Activos totales | US$22.91m |
Actualizaciones recientes sobre salud financiera
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Recent updates
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($22.7M) de ANIX superan a sus pasivos a corto plazo ($2.0M).
Pasivo a largo plazo: Los activos a corto plazo de ANIX ($22.7M) superan a sus pasivos a largo plazo ($213.0K).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ANIX está libre de deudas.
Reducción de la deuda: ANIX no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ANIX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ANIX dispone de suficiente cash runway para 1.4 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 7.8% cada año.